Tuspetinib (HM43239)
Relapsed/Refractory AML
Key Facts
About Aptose Biosciences
Aptose Biosciences is a science-driven biotech focused on developing first-in-class, oral small molecule kinase inhibitors for life-threatening hematologic cancers. Its strategy centers on rationally designed, mutation-agnostic compounds that target multiple key oncogenic pathways to address resistance and broaden efficacy. The company's most advanced assets, tuspetinib for AML and luxeptinib for B-cell malignancies and AML, are in Phase 1/2 development, with promising clinical data generating interest, culminating in a definitive agreement for acquisition by Hanmi Pharmaceutical.
View full company profileAbout Aptose Biosciences
Aptose Biosciences is a science-driven biotech focused on developing first-in-class, oral small molecule kinase inhibitors for life-threatening hematologic cancers. Its strategy centers on rationally designed, mutation-agnostic compounds that target multiple key oncogenic pathways to address resistance and broaden efficacy. The company's most advanced assets, tuspetinib for AML and luxeptinib for B-cell malignancies and AML, are in Phase 1/2 development, with promising clinical data generating interest, culminating in a definitive agreement for acquisition by Hanmi Pharmaceutical.
View full company profileTherapeutic Areas
Other Relapsed/Refractory AML Drugs
| Drug | Company | Phase |
|---|---|---|
| SLS009 (tambiciclib) | SELLAS Life Sciences | Phase 2 |
| Actimab-A (lintuzumab-Ac-225) | Actinium Pharmaceuticals | Phase 2/3 |